Table 1.
Relationship between CISD2 mRNA expression and clinical features in glioma.
| Characteristics | Variable | Low expression of CISD2 | High expression of CISD2 | χ 2 | P |
|---|---|---|---|---|---|
| n | 348 | 348 | |||
|
| |||||
| Age, n (%) | ≤60 | 314 (45.1%) | 239 (34.3%) | 48.2 | <0.001 |
| >60 | 34 (4.9%) | 109 (15.7%) | |||
|
| |||||
| Gender, n (%) | Female | 145 (20.8%) | 153 (22%) | 0.29 | 0.592 |
| Male | 203 (29.2%) | 195 (28%) | |||
|
| |||||
| Histologic grade, n (%) | G2 | 155 (24.4%) | 69 (10.9%) | 180.11 | <0.001 |
| G3 | 137 (21.6%) | 106 (16.7%) | |||
| G4 | 6 (0.9%) | 162 (25.5%) | |||
|
| |||||
| IDH status, n (%) | WT | 43 (6.3%) | 203 (29.6%) | 164.6 | <0.001 |
| Mut | 303 (44.2%) | 137 (20%) | |||
|
| |||||
| 1p/19q codeletion, n (%) | Codel | 101 (14.7%) | 70 (10.2%) | 6.21 | 0.013 |
| Noncodel | 247 (35.8%) | 271 (39.3%) | |||
|
| |||||
| Histological type, n (%) | Astrocytoma | 135 (19.4%) | 60 (8.6%) | 204.2 | <0.001 |
| Glioblastoma | 6 (0.9%) | 162 (23.3%) | |||
| Oligoastrocytoma | 98 (14.1%) | 36 (5.2%) | |||
| Oligodendroglioma | 109 (15.7%) | 90 (12.9%) | |||
|
| |||||
| Primary therapy outcome, n (%) | PD | 62 (13.4%) | 50 (10.8%) | 10.54 | 0.014 |
| SD | 90 (19.5%) | 57 (12.3%) | |||
| PR | 49 (10.6%) | 15 (3.2%) | |||
| CR | 97 (21%) | 42 (9.1%) | |||
CISD2: CDGSH iron sulfur domain 2; IDH: isocitrate dehydrogenase; PD: progressive disease; SD: stable disease; PR: partial response; CR: complete response.